Company: MBIO
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001410578-25-000085
Chunk: 15

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-07
Form: 424B4
Chunk 15
---
 for the manufacture of our product candidates for preclinical and clinical testing and may also do so for commercialization, if and when our product candidates are approved. |

| ● | We rely on clinical data and results obtained by third parties, which may prove inaccurate or unreliable. |

10

| ● | We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. |

Risks Relating to Legislation and Regulation Affecting the Biopharmaceutical and Other Industries

| ● | We operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations, particularly with the new presidential administration in the United States. |

| ● | We may be subject to anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings. |

| ● | We are subject to numerous environmental, health and safety laws and regulations and could become subject to fines or penalties or incur costs that could harm our business. |

Risks Pertaining to Intellectual Property and Potential Disputes with Licensors Thereof

| ● | If we are unable to obtain and maintain sufficient patent protection for our technology and products, our competitors could develop and commercialize products similar or identical to ours and our ability to successfully commercialize our technology and products could therefore be impaired. |

| ● | We depend on our licensors to maintain and enforce the intellectual property rights covering certain of our product candidates. |

| ● | We or our licensors may be subject to costly and time-consuming litigation for infringement of third-party intellectual property rights or to enforce our or our licensors’ intellectual property rights against third-party infringers. |

| ● | Any dispute with our licensors may affect our ability to develop or commercialize our product candidates. |

Risks Relating to Our Control by Fortress Biotech, Inc. (“Fortress”)

| ● | Fortress controls a voting majority of our common stock and has the right to receive significant share grants annually, which will result in dilution of our other stockholders and could reduce the value of our common stock. |

| ● | We have entered into certain agreements with Fortress and may have received better terms from unaffiliated third parties. |

| ● | We share certain directors with Fortress, which could create conflicts of interest